LUND, SWEDEN--(Marketwire - June 30, 2009) - The number of shares and votes in Active Biotech has changed as a consequence of the recently completed rights issue with pre-emptive rights for the shareholders.
Today, the last trading day of the month, there are in total 64,052,238 shares and votes in Active Biotech.
Lund, June 30, 2009 Active Biotech AB (publ) For further information, please contact: Hans Kolam, CFO Tel: +46 (0)46 19 20 44 E-mail: hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex™ for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on June 30, 2009.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
